Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA

Stock Information for CollPlant Biotechnologies Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About CollPlant Biotechnologies Ltd.

Applied DNA Sciences to Begin Trading Under New Ticker 'BNBX' Reflecting Digital Asset Treasury Strategy
Applied DNA Sciences Announces Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation
Applied DNA Abstracts Selected for Poster Presentations Showcasing LineaDNA and LineaIVT Platforms at Upcoming mRNA and CAR T Industry Conferences
Applied DNA Reports Third Quarter Fiscal 2025 Financial Results
Applied DNA Announces New Follow-On LineaDNA Order from Global IVD Manufacturer for Use in Cancer Diagnostic Application
Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements
Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.